Deterioro cognitivo por quimioterapia adyuvante en pacientes con cáncer de mama. Una problemática por definir en el Perú.

Casavilca-Zambrano, Sandro A.; Custodio, Nilton; Cancino-Maldonado, Karina; Liendo-Picoaga, Ruddy; Vidaurre-Rojas, Tatiana

doi:10.20453/rnp.v80i4.3238

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Un tercio presentó dificultad para concentrarse y recordar cosas. Se evidenció déficit cognitivo en pacientes con tratamiento quimioterápico y hormonal; siendo algunos factores de riesgo para ello tener antecedentes de traumatismo encefálico, trastornos neurológicos previos, micrometástasis en sistema nervioso, el nivel de instrucción y coeficiente intelectual 15 . También se evidenció que aquellas pacientes mayores de 50 años presentaban con mayor frecuencia dificultad para concentrarse.…”

Section: Discussionunclassified

Cáncer de mama: ¿Cuánto incide en la calidad de vida?

Elaskar

Solavallone

Sola

et al. 2022

RevOnco

View full text Add to dashboard Cite

El cáncer de mama es la enfermedad maligna más frecuente en mujeres adultas. Considerando la calidad de vida como bienestar en diferentes ámbitos de la vida, es de interés evaluar cómo incide la enfermedad en las pacientes. El objetivo fue determinar la calidad de vida durante el tratamiento. Estudio protocolizado, descriptivo, a través de encuesta validada, dirigida y anónima. Se incluyeron 56 mujeres con cáncer de mama en tratamiento oncológico, de la provincia de Mendoza. Edad promedio 54.2 años. El 41% estaban casadas. Comorbilidades: HTA 34%, tabaquismo 29%, obesidad 23%. El tipo histológico predominante: carcinoma ductal infiltrante 55%. Estadio II 62%. Tratamiento con quimioterapia 91%, radioterapia 4%, hormonoterapia 5%, cirugía 79%. FACT-G (Functional Assessment of Cancer Therapy-General): Bienestar físico: 1/3 sentían falta de energía, más del 50% sintió poco dolor, más del 75% no se sintió enferma. Bienestar social: 50% se sintió cerca de amigos, más de 85% sintió apoyo familiar y 60% estuvo satisfecha con su vida sexual. Bienestar emocional: 1/4 estaban tristes, casi 80% estuvo satisfecha con cómo afrontaban la enfermedad, a más del 50% no le preocupó que la enfermedad/tratamiento ponga en riesgo su vida. Bienestar funcional: más del 60% pudieron trabajar, 66% disfrutaban su vida y aceptaban la enfermedad, 70% se sentía contenta con su calidad de vida, 73% perdió el cabello, a la mitad no les preocupó. Las pacientes subestiman malestares, la mayoría no se sienten enfermas, están esperanzadas y satisfechas en cómo afrontaron su enfermedad. Sin embargo, la enfermedad y el tratamiento afectaron su calidad de vida, reflejándose en las esferas evaluadas.

show abstract

Section: Discussionunclassified

Cáncer de mama: ¿Cuánto incide en la calidad de vida?

Elaskar

Solavallone

Sola

et al. 2022

RevOnco

View full text Add to dashboard Cite

show abstract

“…Most studies state the need for pre-treatment assessment of cognitive functioning in order to establish a baseline against which later results can be compared, once chemotherapy treatment is finished [9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Study of how Clinical and Sociodemographic Variables Influence Chemotherapy-Induced Cognitive Deterioration in Women with Breast Cancer

Martín¹,

Rodríguez²,

Gómez³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Of the many side effects suffered by cancer patients, those related to cognitive performance have become increasingly prominent in clinical practice. We know that chemotherapy generates a series of side effects, such as nausea and vomiting, alopecia, and so on, which can be counteracted by complementary medication. However, in the case of post-chemotherapy cognitive impairment, or chemo brain, these cannot be controlled with drug therapies. However, before any intervention can be considered, it is necessary to know exactly what cognitive impairment is being triggered. For this reason, we decided to study the cognitive status of breast cancer patients. Methods: analytical, prospective, three-measure longitudinal, intrasubject unifactorial, non-probabilistic and accidental assignment study. The sample came from the Medical Oncology Department at Hospital de Salamanca, in Spain. Cognitive function (Trail Making Test and Stroop Test) was established as the primary variable; the presence of sleep disorders (Insomnia Severity Index, ISI) and anaemia (haemoglobin levels in blood) were analysed as secondary variables, in addition to sociodemographic variables (age, stage, type of carcinoma, radiotherapy, menopause, social support network, marital status, years of schooling and employment status). Results: We recruited 151 individuals according to the selection criteria. We can confirm that factors including anaemia, menopause, patient support network and marital status, years of schooling, and employment status did affect the cognitive performance of the patients in active chemotherapy treatment in the study. In contrast, sleep disorders, age, radiotherapy treatment, stage of disease, and type of carcinoma did not affect the cognitive performance of the cancer patients. Conclusions: Chemotherapy does impact the cognitive performance of breast cancer patients.

show abstract

“…Most studies state the need for pre-treatment assessment of cognitive functioning in order to establish a baseline against which later results can be compared [8][9][10][11][12]. This first assessment allows the true magnitude of the change observed after cancer treatment to be studied accurately, in turn allowing its evolution over time to be established.…”

Section: Introductionmentioning

confidence: 99%

Study of How Clinical and Sociodemographic Variables Influence Chemotherapy-induced Cognitive Deterioration in Women with Breast Cancer

Martín¹,

Rodríguez²,

Gómez³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Of the many side effects suffered by cancer patients, those related to cognitive performance have become increasingly prominent in clinical practice. We know that chemotherapy generates a series of side effects, such as nausea and vomiting, alopecia, and so on, which can be counteracted by complementary medication. However, in the case of post-chemotherapy cognitive impairment, or chemo brain, these cannot be controlled with drug therapies. However, before any intervention can be considered, it is necessary to know exactly what cognitive impairment is being triggered. For this reason, we decided to study the cognitive status of breast cancer patients. Methods: analytical, prospective, three-measure longitudinal, intrasubject unifactorial, non-probabilistic and accidental assignment study. The sample came from the Medical Oncology Department at Hospital de Salamanca, in Spain. Cognitive function (Trail Making Test and Stroop Test) was established as the primary variable; the presence of sleep disorders (Insomnia Severity Index, ISI) and anaemia (haemoglobin levels in blood) were analysed as secondary variables, in addition to intervening variables (age, stage, type of carcinoma, radiotherapy, menopause, social support network, marital status, years of schooling and employment status). Results: We recruited 151 individuals according to the selection criteria. We can confirm that factors including anaemia, menopause, patient support network and marital status, years of schooling, and employment status did affect the cognitive performance of the patients in the study. In contrast, sleep disorders, age, radiotherapy treatment, stage of disease, and type of carcinoma did not affect the cognitive performance of the cancer patients. Conclusions: Chemotherapy does impact the cognitive performance of breast cancer patients.

show abstract

Deterioro cognitivo por quimioterapia adyuvante en pacientes con cáncer de mama. Una problemática por definir en el Perú.

Cited by 6 publications

References 0 publications

Cáncer de mama: ¿Cuánto incide en la calidad de vida?

Cáncer de mama: ¿Cuánto incide en la calidad de vida?

Study of how Clinical and Sociodemographic Variables Influence Chemotherapy-Induced Cognitive Deterioration in Women with Breast Cancer

Study of How Clinical and Sociodemographic Variables Influence Chemotherapy-induced Cognitive Deterioration in Women with Breast Cancer

Contact Info

Product

Resources

About